As flu-vaccine heavyweights dispatch their first doses for the upcoming season, they’re planning millions more doses made with next-generation production processes, rather than traditional egg-based manufacturing.
https://www.fiercepharma.com/vaccines/glaxosmithkline-seqirus-begin-shipping-flu-vaccines-for-2018-19-season?mkt_tok=eyJpIjoiTW1OaE5USTROR1k0Tm1FeSIsInQiOiJaTzltYlNmYlV0NHY1d28xQnZ4TTNQbHZXNmkwbUQxa1lodHZWdTJlSVVlVmt5ZXUxTWVUWTk3MlE3Zk4yYUQrd1dnWFZqMDdKNE9oK3BrM1puVlpUT3JvaHJBWWRXbHp1aGM2SHJyOVFWSkw0RTN5N1Z2cHJHRGsxUHpXWEZ2cyJ9&mrkid=11085142